Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985343 · ClinicalTrials.gov registry record · Phase 4
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction
A Phase 4 study, sponsored by Clayton Petro.
- Completed
- Registry status
- Phase 4
- Development phase
- 184
- Enrollment target
NCT05985343: Completed Phase 4 study, sponsored by Clayton Petro.
NCT05985343 is a Phase 4 study that has completed, run by Clayton Petro. The registered enrollment target is 184 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05985343, a Phase 4 study, has completed, sponsored by Clayton Petro.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 184 participants
- Enrollment target
Study Summary
The aim of the study is to determine if the usage of sugammadex would reduce the time to return of bowel function when compared to standard of care (neostigmine/glycopyrrolate) when used for neuromuscular blockade reversal in patients with open abdominal wall reconstruction (AWR).
Primary Outcome
The median time to first postoperative bowel movement and tolerance of solid food (defined as GastroIntestinal-2), as measured in hours, will be recorded for each patient and compared between the two groups.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine / Glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2025-06-02 |
| Phase | Phase 4 |
What the finished NCT05985343 record still lists
NCT05985343 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT05985343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05985343 about?
NCT05985343 is a clinical study titled "The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction". The aim of the study is to determine if the usage of sugammadex would reduce the time to return of bowel function when compared to standard of care (neostigmine/glycopyrrolate) when used for neuromuscular blockade reversal in patients with open abdominal wall reconstruction (AWR).
What is the current status of trial NCT05985343?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2024-01-15. Estimated completion is 2025-06-02.
What interventions are being tested in trial NCT05985343?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine / Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT05985343?
This trial is sponsored by Clayton Petro, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05985343's enrollment target sits among peer trials
184 460th of 2000 higher than 1,538 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI